Personalis Inc

Personalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Personalis Inc excels in Q4 earnings, eyes growth through strategic focus

Personalis Inc's Q4 2022 earnings call highlighted strong financial performance, strategic focus on MRD, and guidance for 2023 amidst market challenges and opportunities.
The company's strengths in partnerships, product innovation, and financial management position it well for future growth and success in a competitive landscape.
While facing challenges in sample delivery, margin expectations, and operational changes, Personalis Inc is poised to leverage opportunities in partnerships, product launches, and market expansion.
Navigating the evolving landscape with resilience and adaptability, Personalis Inc aims to drive growth, profitability, and innovation in the coming year.

Personalis Inc reports strong Q1 revenue growth and oncology progress

Personalis Inc's Q1 2023 performance showcased revenue growth and progress in oncology.
The company aims to launch NeXT Personal for clinical use by Q4 2023, targeting cancer diagnostics.
Challenges include managing expenses, net loss, and ensuring efficient cash usage for financial goals.

Personalis Inc reports Q2 revenue growth, eyes strong collaborations

Personalis Inc is strategically positioned for growth in oncology with NeXT Personal and key collaborations, despite facing financial challenges and revenue fluctuations.
The company's strong balance sheet and prudent expense management offer financial stability and a 2-year cash runway, supporting future growth opportunities.
Legal battles and variability in data publication speed present challenges, but active engagement in scientific advancement and partnerships drive credibility and revenue potential.
Overall, Personalis is navigating a complex landscape with a focus on innovation, financial sustainability, and scientific credibility to drive future success.

Personalis Inc reports strong Q3 growth and strategic partnerships

Personalis Inc's Q3 performance reflects growth in key revenue segments and strategic advancements in cancer research collaborations and product launches.
While facing challenges in net losses and reimbursement coverage, the company's focus on partnerships, operational efficiency, and revenue growth presents opportunities for market expansion.
With a strong cash position, reduced OpEx, and plans for revenue growth, Personalis Inc is poised for strategic growth and market capture in the genomics industry.

Personalis Inc (PSNL) reports robust Q4 performance and strategic growth plans

Personalis Inc (PSNL) delivered strong financial performance in Q4 2023, with revenue growth, improved margins, and cost efficiency measures.
The company's focus on strategic collaborations, strong financial position, and targeted market approach position it well for future growth.
Challenges in revenue guidance, regulatory hurdles, and managing partnerships require careful navigation, but opportunities in key cancer areas offer significant growth potential.

Personalis Inc surpasses revenue targets, eyes MRD test leadership

Personalis Inc demonstrated strong financial performance in Q1 2024, exceeding revenue guidance.
The company's focus on MRD testing and strong IP protections positions it well for future growth.
Challenges lie in balancing test adoption with reimbursement considerations for sustained growth.
Opportunities exist to solidify NeXT Personal's position in clinical diagnostics through strategic planning.

Personalis Inc reports robust Q2 earnings, eyes growth opportunities

Personalis Inc delivered strong financial performance in Q2 2024, driven by revenue growth and strategic initiatives.
The company's focus on MRD testing, partnerships, and innovative strategies position them for future growth.
While challenges like market competition and cash management exist, opportunities in diversification and partnerships are promising.

Personalis Inc reports robust Q3 revenue growth and strategic expansion

Personalis Inc's Q3 performance reflects strong revenue growth and financial stability, underpinned by a focus on innovation and market expansion.
While facing challenges in achieving reimbursement and managing expenses, the company's strategic initiatives position it well for future growth and profitability.
With a clear roadmap for revenue expansion and a commitment to financial efficiency, Personalis Inc is poised to capitalize on growth opportunities in the MRD testing market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Personalis (PSNL) Q1 Earnings Expected to Decline

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it will release its first quarter 2021 financial results after the market closes on Wednesday, May 5, 2021. In conjunction with the release, the Company will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by d

Personalis to Report First Quarter 2021 Financial Results on May 5, 2021

MENLO PARK, Calif.--(BUSINESS WIRE)-- #AACR21--Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform

Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform®

Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Personalis (PSNL) Stock Jumps 7.9%: Will It Continue to Soar?

The stock price of Personalis Inc (NASDAQ: PSNL) has increased by 10.14% today. This is why it happened.

PSNL Stock Price Increased 10.14%: Why It Happened

MENLO PARK, Calif.--(BUSINESS WIRE)-- #immunooncology--Personalis Announces Collaboration with MapKure to Use Personalis' NeXT Platform for Clinical Trials and Companion Diagnostic Development

Personalis Announces Collaboration with MapKure to Use Personalis' NeXT Platform™ for Clinical Trials and Companion Diagnostic Development

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Announces Changes to its Board of Directors

Personalis Announces Changes to its Board of Directors

Personalis, Inc. (PSNL) CEO John West on Q4 2020 Results - Earnings Call Transcript

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the fourth quarter and full year ended December 31, 2020. Fourth Quarter Highlights Record quarterly revenue of $20.2 million in the fourth quarter of 2020 compared with $18.2 million in the fourth quarter of 2019, an 11% increase Record quarterly revenue of $7.6 million from biopharma and all other customers, excluding VA

Personalis Reports Fourth Quarter and Full Year 2020 Financial Results

MENLO PARK, Calif.--(BUSINESS WIRE)--Second paragraph, first sentence of release dated February 11, 2021, should read: Interested parties may access the live call via telephone by dialing (866) 220-8061 for domestic callers or (470) 495-9168 for international callers, using conference ID: 5065084. (instead of Interested parties may access the live call via telephone by dialing (866) 990-1997 for domestic callers or (470) 495-9127 for international callers, using conference ID: 5065084.). The up

CORRECTING and REPLACING Personalis to Report Fourth Quarter 2020 Financial Results on February 25, 2021

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it will release its fourth quarter 2020 financial results after the market closes on Thursday, February 25, 2021. In conjunction with the release, the Company will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live call via telephon

Personalis to Report Fourth Quarter 2020 Financial Results on February 25, 2021

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Expands Leadership Team with Appointment of Susan Moriconi, VP of People and Chief Human Resources Officer

Personalis Expands Leadership Team with Appointment of Susan Moriconi, VP of People and Chief Human Resources Officer

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Thursday, February 18, 2021 at 12:00 p.m. Eastern Time. About Personalis, Inc. Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the la

Personalis to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

The company announced the pricing of a public offering of common stock.

Why Personalis Stock Dropped Today

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced the pricing of its previously announced underwritten public offering of 3,950,000 shares of its common stock at a price to the public of $38.00 per share. Gross proceeds to Personalis from the offering are expected to be $150.1 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, the un

Personalis Announces Pricing of Public Offering of Common Stock

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that it has commenced an underwritten public offering of $150.0 million of its common stock. In addition, Personalis expects to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of common stock on the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to

Personalis Announces Launch of Public Offering of Common Stock

Amphastar Pharma

Evoqua Water Technologies

Barings BDC Inc

Biohaven Pharmaceutical Hld

Colfax

Crh Medical

Global Blood Therapeutics

Hannon Armstrong Sustainable Infrastructure Capital

Houghton Mifflin Harcourt

Lexicon Pharmaceuticals

MannKind

Nektar Therapeutics

Nano-X Imaging

ObsEva

PIMCO Corporate & Income Opportunity Fund

Construction Partners

Surgery Partners

SP Plus

Takeda Pharmaceutical

Cohen & Steers Infrastructure Fund Inc

Xerium Technologies

A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions.

Final Update For My 20/20 Vision For 2020 Dividend Paying Stocks

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2020. Personalis estimates revenue of approximately $20.2 million for the fourth quarter of 2020 compared with $18.2 million in the fourth quarter of 2019, representing an increase of 11%. For the full year 2020, revenue is estimated to be approximately $78.6

Personalis Reports Preliminary Fourth Quarter 2020 Revenue

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that management will present at the 23rd Annual Needham Virtual Growth Conference on Wednesday, January 13, 2021 at 2:45 p.m. Eastern Time. About Personalis, Inc. Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is cur

Personalis to Present at the 23rd Annual Needham Virtual Growth Conference

MENLO PARK, Calif.--(BUSINESS WIRE)-- #AACR20--Personalis Announces the Launch of NEOPS™, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response

Personalis Announces the Launch of NEOPS™, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Announces Delivery of the 100,000th Genome to the U.S. Department of Veterans Affairs Million Veteran Program

Personalis Announces Delivery of the 100,000th Genome to the U.S. Department of Veterans Affairs Million Veteran Program

MENLO PARK, Calif.--(BUSINESS WIRE)-- #EACR--Personalis, Inc. to Present at EACR Liquid Biopsies Virtual Event

Personalis, Inc. to Present at EACR Liquid Biopsies Virtual Event

Exact Sciences

Guardant Health Inc

Illumina

Natera

Multiple companies are working on next-gen blood biopsies tech to detect cancer. The potential market size is big according to most estimates and analysts.

Liquid Biopsy Cancer Testing Is The Next Big Investment Opportunity

MENLO PARK, Calif.--(BUSINESS WIRE)-- #AMP2020--Personalis® to Present at the AMP Annual Meeting 2020

Personalis® to Present at the AMP Annual Meeting 2020

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting

News for Personalis Inc Stock (PSNL)